<DOC>
	<DOC>NCT01303692</DOC>
	<brief_summary>Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent</brief_summary>
	<brief_title>Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent</brief_title>
	<detailed_description>MC MD</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<criteria>Korean prostate cancer over 50 years old with pathological confirmation Patients receiving GnRH antagonist or GnRH agonist plus anti androgen combination within 6 months since starting. Patients measured bone density level before starting to receive hormone therapies above. Patients who are treated other antiosteoporosis drugs and who are treated bisphosphate due to BMD T score below 3.0. Patients who are hard to be analysed by attach to other bone disease. Patients who are hard to be analysed by limitation of chart record according to investigators'discretion.</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>bone mineral loss</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>GnRH agonist alone vs. GnRH agonist plus anti-androgen combination</keyword>
</DOC>